Agenerase Related Published Studies
Well-designed clinical trials related to Agenerase (Amprenavir)
Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers. [2010.03]
Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects. [2009.08]
Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. [2009.08]
Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir. [2007.06.19]
Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir. [2006.08]
Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV. [2006.04]
Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir. [2006.03]
Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. [2005.01.28]
Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir. [2005.01]
Pharmacokinetic and pharmacodynamic analysis of amprenavir-containing combination therapy in HIV-1-infected children. [2004.11]
The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir. [2004.08.01]
Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure. [2004.08]
SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. [2004.07.23]
A randomized study investigating the efficacy and safety of amprenavir in combination with low-dose ritonavir in protease inhibitor-experienced HIV-infected adults. [2004.07]
Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients. [2004.07]
Impact of insertions in the HIV-1 p6 PTAPP region on the virological response to amprenavir. [2004.04]
Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. [2004.04]
Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. [2004.01]
HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations. [2003.11]
Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapy. [2003.09]
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. [2003.08]
Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients. [2003.06.10]
Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers. [2003.01]
Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers. [2002.08]
The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850). [2002.07.15]
Single-dose pharmacokinetics of amprenavir coadministered with grapefruit juice. [2002.05]
Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir. [2002.03]
Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. [2002.03]
Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir. [2001.12]
Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers. [2001.05.25]
A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir. [2001.04.15]
In vivo effect of alpha(1)-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor. [2001.03]
Safety profile and tolerability of amprenavir in the treatment of adult and pediatric patients with HIV infection. [2000.12]
Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team. [2000.09]
Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers. [2000.04]
A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team. [1999.12.03]
Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men. [1999.12]
Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults. [1999.07]
Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. [1999.04]
Well-designed clinical trials possibly related to Agenerase (Amprenavir)
In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients. [2010]
The acute effects of HIV protease inhibitors on insulin suppression of glucose production in healthy HIV-negative men. [2009.10.01]
Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients. [2006]
Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy. [2006]
The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals. [2005.09.02]
Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. [2003.01]
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. [2002.07.10]
Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults. [2001.06]
The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850). [2000.05]
Sampling lymphoid tissue cells by ultrasound-guided fine needle aspiration of lymph nodes in HIV-infected patients. Swiss HIV Cohort Study. [1999.08.20]
Other research related to Agenerase (Amprenavir)
Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study). [2011.08]
Food-dependent disintegration of immediate release fosamprenavir tablets: in vitro evaluation using magnetic resonance imaging and a dynamic gastrointestinal system. [2011.02]
Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers. [2010.10]
Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of
unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate
in healthy volunteers. [2010]
Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment. [2009.12]
A liquid chromatography-tandem mass spectrometry assay for quantification of nevirapine, indinavir, atazanavir, amprenavir, saquinavir, ritonavir, lopinavir, efavirenz, tipranavir, darunavir and maraviroc in the plasma of patients infected with HIV. [2009.10.01]
Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II). [2009.05]
Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis. [2009.03]
Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects. [2008.07]
Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen. [2008.05]
Determination of abacavir, amprenavir, didanosine, efavirenz, nevirapine, and stavudine concentration in human plasma by MALDI-TOF/TOF. [2008.03.01]
Predictive value of the HIV phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual protease inhibitor regimen. [2008.02.19]
Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients. [2008.02]
Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects. [2008.02]
Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus. [2008.01]
Same patient, new stone composition: amprenavir urinary stone. [2008]
Pharmacokinetic Interaction between Fosamprenavir/Ritonavir and Rifabutin in Healthy Subjects. [2007.12.03]
[Pharmacokinetics of amprenavir in HIV-1 patients with renal insufficiency] [2007.12]
Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects. [2007.11]
Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. [2007.10.18]
Parallel monitoring of plasma and intraluminal drug concentrations in man after oral administration of fosamprenavir in the fasted and fed state. [2007.10]
Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment. [2007.10]
Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers. [2007.10]
Development and evaluation of an immunoassay for the monitoring of the anti-HIV drug amprenavir. [2007.08.31]
Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged. [2007.08]
Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir. [2007.07.11]
Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir and correlation with plasma levels. [2007.07]
Fosamprenavir calcium plus ritonavir for HIV infection. [2007.06]
Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients. [2007.05.31]
Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks. [2007.05]
Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients. [2007.04]
Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers. [2007.02]
Salvage therapy with amprenavir, lopinavir and ritonavir is durably potent in HIV-infected patients in virological failure: 1-year results. [2007.01.11]
Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz. [2007]
Long-Term Results of Initial Therapy With Abacavir and Lamivudine Combined With Efavirenz, Amprenavir/Ritonavir, or Stavudine. [2006.11.01]
Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects. [2006.09]
Fosamprenavir: drug development for adherence. [2006.07]
Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation. [2006.05]
Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. [2006.05]
Amprenavir-induced maculopapular exanthem followed by desensitization in a patient with late-stage human immunodeficiency virus. [2006.04]
Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection. [2006.04]
Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug. [2006]
Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals. [2005.08]
Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients. [2005.08]
Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography. [2005.04]
Salvage therapy with ritonavir-boosted amprenavir/fosamprenavir: virological and immunological response in two years follow-up. [2005.03]
Single-dose safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, in HIV-infected children. [2005.01]
Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile. [2005]
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients. [2004.11.01]
Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects. [2004.09]
Effectiveness and tolerability of a once-daily amprenavir/ritonavir-containing highly active antiretroviral therapy regimen in antiretroviral-naive patients at risk for nonadherence: 48-week results after 24 weeks of directly observed therapy. [2004.09]
Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients. [2004.09]
|